Allergy Therapeutics PLC

Allergy Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)6.25
  • Today's Change0.00 / 0.00%
  • Shares traded608.43k
  • 1 Year change-71.59%
  • Beta1.2312
Data delayed at least 20 minutes, as of Dec 30 2022 12:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

  • Revenue in GBP (TTM)72.77m
  • Net income in GBP-13.78m
  • Incorporated2004
  • Employees601.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Hellenic Dynamics PLC-100.00bn-100.00bn21.61m25.00--1.61----------0.0011----------------------------0.00--------------
Science in Sport PLC65.55m-12.54m25.86m218.00--0.5553--0.3945-0.0913-0.09130.47820.27010.94984.014.95300,706.40-18.17-9.41-24.12-11.3045.6749.61-19.13-11.800.6709-29.530.2825--24.2138.56-294.50--46.77--
Skinbiotherapeutics PLC129.80k-3.00m26.84m12.00--20.04--206.75-0.0192-0.01920.00080.00770.03930.18430.361110,816.67-90.97-38.99-108.04-41.8564.48---2,313.31-10,323.931.64-330.700.0828-------94.88--4.10--
Destiny Pharma PLC0.00-6.50m28.39m20.00--2.87-----0.0928-0.09280.000.1040.00----0.00-76.16-47.98-85.94-52.05------------0.00-------21.80---45.97--
Chill Brands Group PLC-430.07k-5.29m32.36m5.00--28.73-----0.0235-0.0237-0.00190.0039-0.08090.0349---86,014.00-99.49-59.54-120.93-81.31-------455.175.21--0.7817--94.52---16.08---31.94--
Tissue Regenix Group PLC19.66m-2.17m36.10m79.00--1.44--1.84-0.0308-0.03080.27950.35680.53061.285.50248,893.00-5.63-16.79-6.25-18.4146.0046.19-10.61-43.221.68-2.460.2402--23.9529.4343.76--30.58--
Poolbeg Pharma PLC0.00-4.69m40.50m12.00--2.21-----0.0094-0.00940.000.0367------0.00--------------------0.00-------100.60------
C4X Discovery Holdings PLC4.31m-7.52m41.16m48.00--3.04--9.55-0.0314-0.03140.0180.05380.2643--7.5789,770.84-46.14-52.11-51.65-59.3597.8498.57-174.56-206.69---5,085.000.0415---52.1679.96-112.28---16.47--
Allergy Therapeutics plc72.77m-13.78m42.44m601.00--1.06--0.5833-0.022-0.0220.10940.05870.90022.098.72---17.04-2.20-21.93-2.8768.0373.25-18.93-2.091.74-29.720.2152---13.712.56-577.34--13.67--
Venture Life Group PLC43.98m520.00k47.12m153.00106.430.62287.981.070.00350.00350.32970.59810.38422.503.07287,451.000.45431.750.51512.0140.1740.301.184.411.342.190.26190.0034.2422.33-78.35--37.59--
Shield Therapeutics PLC4.47m-40.44m48.13m23.00--3.77--10.77-0.1661-0.16610.01880.01790.13441.601.08---121.66-38.57-154.17-43.0944.7180.67-905.40-253.150.8118--0.5291--194.0847.63-105.53---11.08--
CRUSHMETRIC Group Ltd910.93k-195.99k48.23m6.00------52.95-0.0022-0.00220.0104-0.04741.065.145.24---64.23-118.75----46.1238.24-60.68-156.870.0909-10.54-----75.86-14.62-156.85------
Spectral MD Holdings Ltd20.38m-2.34m61.67m71.00--6.36--3.03-0.0173-0.01730.15050.07121.36--13.61287,030.00-15.63---22.32--42.72---11.48-----12.730.0788--66.47--44.50------
Data as of Dec 30 2022. Currency figures normalised to Allergy Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
JPMorgan Chase Bank, NA (Investment Management)as of 02 Mar 2023124.00m0.00%
River & Mercantile Asset Management LLPas of 10 Apr 202328.70m0.00%
Odey Asset Management LLPas of 02 Mar 20239.16m0.00%
Medical Strategy GmbHas of 31 Jan 20233.64m0.00%
Hargreaves Lansdown Asset Management Ltd.as of 02 Mar 20233.54m0.00%
Santander Asset Management SA SGIICas of 02 Mar 20233.13m0.00%
Hauck Aufh�user Lampe Privatbank AGas of 02 Mar 20233.07m0.00%
West Yorkshire Pension Fundas of 02 Mar 20231.98m0.00%
Maitland Asset Management (Pty) Ltd.as of 02 Mar 20231.90m0.00%
Ninety One UK Ltd.as of 31 Aug 20221.90m0.00%
More ▼
Data from 30 Sep 2021 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.